Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...

Full description

Bibliographic Details
Main Authors: Yuyin Fu, Yujia Peng, Shengyan Zhao, Jun Mou, Lishi Zeng, Xiaohua Jiang, Chengli Yang, Cheng Huang, Yuyan Li, Yin Lu, Mengdan Wu, Yanfang Yang, Ting Kong, Qinhuai Lai, Yangping Wu, Yuqin Yao, Yuxi Wang, Lantu Gou, Jinliang Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
foretinib
anti-PD-1
combination therapy
immunotherapy
tumor microenvironment
colon cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.689727/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.689727/full

Similar Items